非酒精性脂肪肝
内科学
医学
荟萃分析
置信区间
胰岛素抵抗
脂肪肝
胃肠病学
体质指数
随机对照试验
胆固醇
传统医学
内分泌学
胰岛素
疾病
作者
Fariborz Mansour‐Ghanaei,Amir Hadi,Makan Pourmasoumi,Farahnaz Joukar,Sahar Golpour,Ameneh Najafgholizadeh
摘要
This study aimed to evaluate the efficacy of green tea supplementation on nonalcoholic fatty liver disease treatment. Electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar, were systematically searched up to October 30, 2017, to identify eligible trials based on the inclusion criteria. The effect size was presented as mean difference with 95% confidence intervals (CI). The meta‐analysis of data from four studies indicated significant effects of green tea supplementation in altering alanine aminotransferases (−12.81 U/L; 95% CI: −18.17 to −7.45) and aspartate aminotransferases (−10.91 U/L; 95% CI: −19.66 to −2.17) blood concentrations. Likewise, a favorable effect of green tea administration was observed on body mass index (−2.08 kg/cm2; 95% CI: −2.81 to −1.36), triacylglycerol (−31.87 mg/dl; 95% CI: −40.62 to −23.12), total cholesterol (−27.57 mg/dl; 95% CI: −36.17 to −18.98), and low‐density lipoprotein cholesterol (−14.15 mg/dl; 95% CI: −23.69 to −4.60), whereas no significant effect was detected on high‐density lipoprotein cholesterol concentrations (7.41 mg/dl; 95% CI: −1.49 to 16.30) and homeostasis model assessment of insulin resistance (−4.06; 95% CI: −10.22 to 2.09). This systematic review and meta‐analysis of available trials suggests that there are potential benefits of green tea supplementation on nonalcoholic fatty liver disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI